| GBLX Stock | | | USD 0.01 0 4,900% |
VP
Mr. Krin Ellery Kuethe is a Senior Vice President Cultivation of the Company since 2018. Mr. Kuethe has participated in all phases of development within the medical marijuana industry. Prior to joining the Company in June 2016, he setup, built out, and acquired approved licensing to manage and operate the fasted growing, state licensed cultivation and retail dispensary facilities in state of Arizona. He simultaneously designed and managed statecompliant facilities for the production of medical marijuana edibles and concentrates, and other dispensary services approved by the states of Arizona and California. In addition to providing operational roadmaps to ensure proven large scale commercial cannabis cultivation success, profitability, and compliance with regulatory standards, Mr. Kuethe has consulted and participated in various equity financing transactions which led him to own several successful businesses within the broad range of cannabisindustry support services and products. Mr. Kuethes facilities showcase the cuttingedge industry technology as well as provide key education to the county and state regarding finance, operations, and public interface. since 2018.
| Age | 39 |
| Tenure | 6 years |
| Phone | 866 721 0297 |
| Web | https://www.gbsciences.com |
GB Sciences Management Efficiency
The company has return on total asset
(ROA) of
(0.2082) % which means that it has lost $0.2082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(50.9796) %, meaning that it created substantial loss on money invested by shareholders. GB Sciences' management efficiency ratios could be used to measure how well GB Sciences manages its routine affairs as well as how well it operates its assets and liabilities.
GB Sciences currently holds 397.31
K in liabilities with Debt to Equity
(D/E) ratio of 1.07, which is about average as compared to similar companies. GB Sciences has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist GB Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, GB Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GB Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GBLX to invest in growth at high rates of return. When we think about GB Sciences' use of debt, we should always consider it together with cash and equity.
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada. Growblox Sciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people. GB Sciences [GBLX] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
GB Sciences Leadership Team
Elected by the shareholders, the GB Sciences' board of directors comprises two types of representatives: GB Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GBLX. The board's role is to monitor GB Sciences' management team and ensure that shareholders' interests are well served. GB Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GB Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
GBLX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GB Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for GBLX Pink Sheet Analysis
When running GB Sciences' price analysis, check to
measure GB Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GB Sciences is operating at the current time. Most of GB Sciences' value examination focuses on studying past and present price action to
predict the probability of GB Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GB Sciences' price. Additionally, you may evaluate how the addition of GB Sciences to your portfolios can decrease your overall portfolio volatility.